InsiderTrades.com logo
Eben Tessari net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Eben Tessari Biography and Net Worth

https://monarchcasino.com/corporategovernance_boardofdirectors.asp of Kiniksa Pharmaceuticals

Eben joined Kiniksa as it was founded in 2015. He was initially Chief Business Officer where he oversaw long-range strategic planning, forecasting, decision analysis, business development, licensing, valuation, and new product strategy.  In January 2022, Eben was promoted to Chief Operating Officer where he oversees our functional leadership teams in business development, program management, clinical development, manufacturing, and research. Before Kiniksa, he was Senior Director and Head of Business Development at Synageva BioPharma. Prior to that he was Director, Business and Corporate Development for Civitas Therapeutics. There he played a lead role in managing the company through a dual-path IPO process which led, ultimately, to a successful acquisition by Acorda Therapeutics. Before joining Civitas, he worked in a variety of roles with increasing responsibility at Vertex Pharmaceuticals, Zalicus, and EPIX Pharmaceuticals. Eben holds a BS in behavior neuroscience from Northeastern, an MS in biomedical engineering from Boston University and both a JD and MBA from Suffolk University. 

What is Eben Tessari's net worth?

The estimated net worth of Eben Tessari is at least $1.82 million as of February 10th, 2025. Mr. Tessari owns 81,975 shares of Kiniksa Pharmaceuticals stock worth more than $1,816,566 as of March 14th. This net worth evaluation does not reflect any other assets that Mr. Tessari may own. Additionally, Mr. Tessari receives an annual salary of $733,290.00 as https://monarchcasino.com/corporategovernance_boardofdirectors.asp at Kiniksa Pharmaceuticals. Learn More about Eben Tessari's net worth.

How old is Eben Tessari?

Mr. Tessari is currently 42 years old. There are 5 older executives and no younger executives at Kiniksa Pharmaceuticals. The oldest executive at Kiniksa Pharmaceuticals is Dr. John F. Paolini FACC, M.D., Ph.D., Senior VP & Chief Medical Officer, who is 59 years old. Learn More on Eben Tessari's age.

What is Eben Tessari's salary?

As the https://monarchcasino.com/corporategovernance_boardofdirectors.asp of Kiniksa Pharmaceuticals, Ltd., Mr. Tessari earns $733,290.00 per year. There are 2 executives that earn more than Mr. Tessari. The highest earning executive at Kiniksa Pharmaceuticals is Mr. Sanj K. Patel, CEO & Chairman of the Board, who commands a salary of $1,570,000.00 per year. Learn More on Eben Tessari's salary.

How do I contact Eben Tessari?

The corporate mailing address for Mr. Tessari and other Kiniksa Pharmaceuticals executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals can also be reached via phone at (781) 431-9100 and via email at ir@kiniksa.com. Learn More on Eben Tessari's contact information.

Has Eben Tessari been buying or selling shares of Kiniksa Pharmaceuticals?

Over the course of the past ninety days, Eben Tessari has sold $529,340.00 in Kiniksa Pharmaceuticals stock. Most recently, Eben Tessari sold 14,000 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a transaction totalling $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares of the company's stock, valued at $1,604,250.75. Learn More on Eben Tessari's trading history.

Who are Kiniksa Pharmaceuticals' active insiders?

Kiniksa Pharmaceuticals' insider roster includes Michael Megna (Group Vice President of Finance and Chief Accounting Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Kiniksa Pharmaceuticals?

In the last year, insiders at the sold shares 11 times. They sold a total of 333,156 shares worth more than $8,367,632.36. The most recent insider tranaction occured on February, 10th when COO Eben Tessari sold 14,000 shares worth more than $273,980.00. Insiders at Kiniksa Pharmaceuticals own 54.6% of the company. Learn More about insider trades at Kiniksa Pharmaceuticals.

Information on this page was last updated on 2/10/2025.

Eben Tessari Insider Trading History at Kiniksa Pharmaceuticals

See Full Table

Eben Tessari Buying and Selling Activity at Kiniksa Pharmaceuticals

This chart shows Eben Tessari's buying and selling at Kiniksa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$529ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Kiniksa Pharmaceuticals Company Overview

Kiniksa Pharmaceuticals logo
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More

Today's Range

Now: $22.69
Low: $22.02
High: $22.86

50 Day Range

MA: $19.90
Low: $18.17
High: $22.50

2 Week Range

Now: $22.69
Low: $16.56
High: $28.15

Volume

74,086 shs

Average Volume

404,925 shs

Market Capitalization

$1.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48